The Office of Health Economics: Adult Vaccination Programmes Deliver Socio-economic Benefits up to 19 Times Initial Investment, According to New Report
A new report published today reveals that adult vaccination programmes can return up to 19 times their initial investment when the full spectrum of economic and societal benefits is valued. The 19x return is equivalent to up to USD 4,637 in net monetary benefits to society per individual full vaccination course.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240417519822/en/
Learn more about the economic benefits of investing in adult immunisation programmes in a new study by the Office of Health Economics (OHE). Graphic: OHE
The study, a first-of-its-kind analysis of adult immunisation programmes by the Office of Health Economics (OHE) and commissioned by IFPMA (1), looked at four adult vaccines across ten countries where they are available to determine the wider economic and social impact.
Focusing on vaccines that protect against influenza (flu), pneumococcal disease, respiratory syncytial virus (RSV), and herpes zoster (shingles), the research looks at the delivery of vaccine programmes in countries that represent a range of healthcare systems, demographics, and vaccine schedules - Australia, Brazil, France, Germany, Italy, Japan, Poland, South Africa, Thailand, and the United States.
The report concludes that the vaccination programmes deliver substantial returns on government investment through cost savings within healthcare systems and wider socio-economic benefits. Preventing illness reduces doctor and hospital visits, meaning valuable resources can be allocated elsewhere, and ensuring a healthy and active workforce throughout life can boost economic productivity.
The data also demonstrates that adult immunisation can deliver socio-economic returns proportional to childhood immunisation programmes (2). Despite this, access to adult vaccination is inconsistent around the world, with limited inclusion in routine immunisation schedules.
Professor Lotte Steuten, Deputy CEO of OHE, and co-author of the report, said:
“Increasing pressures on ailing healthcare systems, such as ageing populations, are driving an urgent need to shift to a prevention-first mindset. Our report sets out a compelling case for adult immunisation programmes playing a key role in the shift to prevention.
“Our findings show that costs are offset multiple times over by benefits to society when governments invest in adult immunisation programmes. These returns are realised through benefits to individuals, families, and communities, providing a clear call to action to countries not already implementing or expanding robust vaccination schedules.”
The researchers used an established vaccine value framework to gather evidence but discovered a lack of data across many elements. This finding, coupled with a lack of agreed methods for capturing some elements, means the positive returns shown are likely to be underestimates of the full value that adult vaccines bring to society.
The report has been released ahead of the WHO’s World Immunisation Week, and addressing such evidence gaps will be critical in meeting the ambition of the Immunization Agenda 2030. This includes a strategic priority to ensure that ‘all people benefit from recommended immunizations throughout the life-course’ and explicitly outlines the need for data guided implementation.
Laetitia Bigger, IFPMA Vaccines Policy Director, added:
“This important study widens the lens to demonstrate that adult vaccination programmes are delivering real benefits for health systems and societies across the globe.
“Vaccines are one of the most effective public health measures and can also be a powerful driver of more productive economies and resilient societies.
“It is critical that these benefits are better understood if we are to ensure that people who can benefit from adult immunisation programmes are able to access them.”
Maarten Postma, Professor in Pharmacoeconomics at the University of Groningen (Netherlands) and reviewer of the report’s methodology, commented:
“Assessing the value of adult immunisation provides policymakers with a clearer picture of the associated benefits and costs. This comprehensive report looked at four adult vaccines internationally and employed a rigorous methodological framework to assess their value."
(1) The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) is the innovative pharmaceutical industry’s representative in official relations with the United Nations.
(2) Using the value-of-a-statistical-life approach, return on investment for 10 childhood vaccination programmes was 51.0 from 2011 to 2020 and 52.2 from 2021 to 2030 (Source: https://www.healthaffairs.org/doi/10.1377/hlthaff.2020.00103).
- ENDS -
Notes to editors
About the report
The full report ‘The Socio-Economic Value of Adult Immunisation Programmes’ is available at: https://www.ohe.org/publications/the-socio-economic-value-of-adult-immunisation-programmes/
About OHE
With over 60 years of expertise, the Office of Health Economics (OHE) is the world’s oldest independent health economics research organisation. Every day we work to improve health care through pioneering and innovative research, analysis, and education.
As a global thought leader and publisher in the economics of health, health care, and life sciences, we partner with Universities, Government, health systems and the pharmaceutical industry to research and respond to global health challenges.
As a government–recognised Independent Research Organisation and not–for–profit, our international reputation for the quality and independence of our research is at the forefront of all we do. OHE provides independent and pioneering resources, research and analyses in health economics, health policy and health statistics. Our work informs decision–making about health care and pharmaceutical issues at a global level.
All of our work is available for free online at www.ohe.org
About IFPMA
The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) represents over 90 innovative pharmaceutical companies and associations around the world. Our industry’s almost three million employees discover, develop, and deliver medicines and vaccines that advance global health. Based in Geneva, IFPMA has official relations with the United Nations and contributes industry expertise to help the global health community improve the lives of people everywhere. For more information, visit ifpma.org.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240417519822/en/
Contact information
For further details, including high-resolution photos, or to arrange a briefing or interview, please contact:
Tim Watson
Director of Marketing & Communications,
Office of Health Economics
T: +44 (0)7866 288456
E: twatson@ohe.org
About Business Wire
Business Wire(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Sustainability Regulation Propelling Transformation in Corporate Reporting, According to New Survey by Workiva30.4.2024 12:00:00 CEST | Press release
The majority (81%) of companies not subject to the European Union’s Corporate Sustainability Reporting Directive (CSRD) intend to partially or fully align their sustainability disclosures with its requirements, according to an independent survey commissioned by Workiva Inc. (NYSE:WK). The third annual 2024 ESG Practitioner Survey polled more than 2,000 people involved in corporate reporting, including finance and accounting, sustainability, risk, and internal audit professionals across North America, Europe, and Asia. “The adoption of the CSRD was a pivotal moment, marking the first major regulation calling for integrated financial and sustainability disclosures with third-party assurance. Now, as companies around the world gear up for their first mandated CSRD reports in 2025, we’re seeing CSRD’s impact extend far beyond those subject to the regulation,” said Paul Volpe, Senior Vice President of Growth Solutions at Workiva. “The CSRD has initiated a global shift toward assured integra
Horizon3.ai Unveils Rapid Response Service for Cyber Resilience30.4.2024 12:00:00 CEST | Press release
Horizon3.ai, a pioneer in autonomous security solutions, today announced the launch of its Rapid Response service, now part of the NodeZero™ platform. This one-of-a-kind capability marks a significant advancement in autonomous penetration testing solutions by addressing a critical gap in measuring the real-world impact of exploitable vulnerabilities within the software many organizations have come to rely on. Now, organizations can gain a clear understanding of their ‘likelihood of exploitability’ for the most critical vulnerabilities being announced. As organizations continue to contend with both zero-day and N-day vulnerabilities, the window of time between the public disclosure of a vulnerability and threat actors exploiting them in the wild is steadily shrinking. Knowing this predicament, organizations spend vast amounts of time, money, and resources patching the software they use after hearing of a vendor vulnerability announcement. Yet, how often are organizations expending consi
Sovos Introduces Indirect Tax Suite to Meet Complexities of Global Compliance30.4.2024 12:00:00 CEST | Press release
Sovos, the always-on compliance company, introduces its Indirect Tax Suite, a comprehensive, integrated solution to modernize how companies meet global indirect tax obligations. Part of the Sovos Compliance Cloud, the Indirect Tax Suite empowers enterprises to manage all of their indirect tax obligations with governments, buyers, suppliers and consumers. “Companies operating across multiple markets – or looking to enter new markets – face three distinct challenges in meeting their indirect tax obligations: variations in tax rates and rules; reporting cadences that can range from months later to real-time; and vastly different documenting and storage requirements for transaction data. Keeping up with all of this is a tremendous drain on resources, especially when using multiple, disconnected point systems for different obligations or in different countries,” said Kevin Akeroyd, CEO, Sovos. “With the Sovos Indirect Tax Suite, companies can rely on the only comprehensive, global, always-o
Forrester Announces Full Conference Agenda For CX Summit EMEA 202430.4.2024 10:00:00 CEST | Press release
Forrester (Nasdaq: FORR) today announced the full conference agenda for its CX Summit EMEA event being held in London and digitally on June 24-26, 2024. Today, customers expect more personalised services that reflect their unique preferences and behaviours. With the advances in AI, companies now have an opportunity to integrate generative AI (genAI) tools with human capabilities to deliver more intuitive and responsive customer experiences (CX) that foster loyalty and satisfaction. However, the socioeconomic and cultural differences in Europe, combined with new AI regulations, pose a challenge, requiring a deep understanding of how to effectively integrate human and AI experiences, while managing the new and complex regulatory landscape. Featuring immersive experiences, keynote presentations, case studies, and dedicated breakout sessions, CX Summit EMEA will offer the latest research and frameworks to help CX, digital, and B2C marketing leaders understand how AI will transform customer
Merge Expands Footprint in Europe, Facilitating Product Integrations for GDPR-Compliant Companies30.4.2024 10:00:00 CEST | Press release
Merge, which provides unified APIs for B2B SaaS organizations to easily add hundreds of integrations to their products, has officially expanded to Europe with the establishment of its Berlin-based team. The expansion reinforces Merge’s commitment to serving European customers’ integration wants and needs effectively. Data protection has been a top priority for European organizations since The General Data Protection Regulation (GDPR) took effect in 2018. As a result, Merge remains steadfast in prioritizing investments in security, product infrastructure, and support to assist European companies with their product integration needs. To ensure the highest standards of security and compliance, Merge maintains ISO 27001 and SOC 2 Type 2 certifications. Additionally, Merge puts in place Data Processing Agreements (DPAs) with all customers, committing to processing data transfers in accordance with GDPR’s Standard Contractual Clauses. Furthermore, Merge supports both multi-tenant and single-